

ASX ANNOUNCEMENT

24 July 2020

Share sale facility for holders of less than marketable parcels closes

Following the announcement of the Company's facility for the sale of Unmarketable Parcels (UMP) **Respiri Limited (ASX:RSH) ("Respiri" or the "Company")**, an eHealth SaaS Company supporting respiratory health management, confirms that this facility is now closed.

As per section 3.3 of the Company's Constitution and based on the ASX closing price of RSH's shares (\$0.073) on 29 May 2020 (being the Record Date) the Directors determined a less than marketable parcel was any shareholding of less than 6,850 shares.


Shareholders with Unmarketable Parcels were issued instructions on 2 June 2020 and then again on 14 July 2020 to return the Share Retention Form, or top up their holding, by no later than 5.00 pm (AEST time) on Monday 21 July 2020 (being the final Closing Date) if they wished to retain their shareholding.

The Company confirms that 2,208 Minority Members elected not to opt out of this program. These shareholders held 1,692,095 shares as of 22 July 2020 (being the Date of Effect).

The Company also confirms that it received offers on 22 July 2020 for the purchase of all 1,692,095 shares available for sale under the UMP Facility. These offers were accepted at a price of \$0.1168 per share which was equal to the Authorised Price on 22 July 2020. All shares have been sold. The shares have been placed with a long term investor as part of a strategic investment in the Company's future beyond the planned launch at the end of this calendar year.

In accordance with section 3.8 of the Company's Constitution sale proceeds will be sent to Minority Members whose holdings have been sold under the UMP Facility within 14 days of the share sales, or by August 5th.

Sale proceeds will be paid in Australian dollars via the payment method recorded on the RSH register, by either direct credit or cheque. Minority Members with a registered address outside of Australia on the Date of Effect will be paid their sale proceeds in Australian dollars via a cheque sent in the post. In the case where a Minority Member's whereabouts are unknown the proceeds of sale shall be applied in accordance with the applicable laws in Victoria dealing with unclaimed monies.



Alastair Beard
Company Secretary
Respiri Limited
E: alastair@respiri.co

- ENDS -

This ASX announcement dated 24 July 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co